



# Medical innovations against infectious diseases: strategies and preventive measures, diagnosis and treatment

Innovaciones médicas contra enfermedades infecciosas: estrategias y medidas preventivas, diagnóstico y tratamiento

144

Sofya Sergeevna Melnikova. Tyumen state medical university Odesskaya, 54, 625023 russia, tyumen. <https://orcid.org/0009-0008-0227-4693>. Sonyamelnikova@gmail.com

Zulay Isaevna Magamadova Federal State Budgetary Educational Institution of Higher Education «Ingush State University (IngSU)» Medical Faculty 386001, Magas, ZIAZIKOVA. str. 7. <https://orcid.org/0009-0006-9391-3862>. tantay777z@mail.ru

Shikh Sultan Ruslanovich Karaev. Kursk State Medical University Street Karl Marx 3 | 305004 | Russia. <https://orcid.org/0009-0009-5617-1291>. Shihsoltan@gmail.com

Elizaveta Dmitrievna Nikitina, Saratov State Medical University named after V. I. Razumovsky, Bolshaya Kazachia st., 112 Saratov, 410012 Russia, 0009-0009-2981-1695, nikitinaelizavetasgmu@gmail.com

Andrey Igorevich Nazin. First Pavlov State Medical University of St. Petersburg. L'va Tolstogo str. 6-8, Saint Petersburg, 197022, Russia. <https://orcid.org/0009-0007-9100-4339>. Andrew.nazin@yandex.ru

Artyom Sergeevich Markin. Federal State Budgetary Educational Institution of Higher Education "National Research Ogarev Mordovia State University" 430005, 68 Bolshevistskaya Str., Saransk 430005, Republic of Mordovia, Russia. <https://orcid.org/0009-0002-5750-8430>. art.mar.kin123@gmail.com

Muslim Ramzanovich Khazhgiriev Saratov State Medical University named after V.I. Razumovsky Street Bolshaya Kazachia 112, 410012, Russia. <https://orcid.org/0009-0008-2055-0532>. mkhazhgiriev@mail.ru

Yusup Emilkhanovich Tokaev. Federal State Budgetary Educational Institution of Higher Education «Astrakhan State Medical University» Medical Faculty 414000, Astrakhan, Bakinskaya str. 121. <https://orcid.org/0009-0000-2886-9582>. yusup.tokk@mial.ru

Received: 01/20/2022 Accepted: 04/19/2023 Published: 05/12/2024 DOI: <http://doi.org/10.5281/zenodo.11260418>

## Abstract

The article presents an overview of modern medical innovations aimed at combating infectious diseases, which remain one of the main challenges for public health worldwide. The paper examines and analyzes in detail the key strategies of prevention, diagnosis and treatment based on advanced scientific and technological achievements. Special attention is paid to the development and application of vaccines, including innovative approaches to their creation, such as RNA vaccines and vector vaccines, as well as strategies to strengthen the immune system through the development of adjuvants and new delivery methods. To that aim, an extensive review of modern scientific articles, reviews, books and other publications related to medical innovations in the field of combating infectious diseases was carried out. The latest diagnostic methods are being investigated, including the use of molecular technologies, biosensors and artificial intelligence for more accurate and rapid detection of infections. In conclusion, the importance of a continuous innovative approach in combating the growing challenges of infectious diseases on a global scale and the need for global cooperation to effectively overcome these problems is emphasized.

**Keywords:** infectious diseases, medical innovations, prevention strategies, diagnosis, treatment.

## Resumen

El artículo presenta una visión general de las innovaciones médicas modernas destinadas a combatir las enfermedades infecciosas, que siguen siendo uno de los principales desafíos para la salud pública en todo el mundo. El artículo examina y analiza en detalle las estrategias clave de prevención, diagnóstico y tratamiento basadas en logros científicos y tecnológicos avanzados. Se presta especial atención al desarrollo y aplicación de vacunas, incluidos enfoques innovadores para su creación, como vacunas de ARN y vacunas de vectores, así como estrategias para fortalecer el sistema inmunológico mediante el desarrollo de adyuvantes y nuevos métodos de administración. Para ello se llevó a cabo una extensa revisión de artículos científicos modernos, reseñas, libros y otras publicaciones relacionadas con las innovaciones médicas en el campo de la lucha contra las enfermedades infecciosas. Se están investigando los últimos métodos de diagnóstico, incluido el uso de tecnologías moleculares, biosensores e inteligencia artificial para una detección más precisa y rápida de infecciones. En conclusión, se enfatiza la importancia de un enfoque innovador continuo en la lucha contra los crecientes desafíos de las enfermedades infecciosas a escala global y la necesidad de una cooperación global para superar eficazmente estos problemas.

**Palabras clave:** enfermedades infecciosas, innovaciones médicas, estrategias de prevención, diagnóstico, tratamiento.

## Introduction

Infectious diseases remain one of the most serious threats to public health worldwide, contributing significantly to morbidity, mortality and economic losses<sup>1</sup>. Despite significant advances in medical science and practice, bacterial, viral, fungal and other infections caused by them continue to cause an urgent need to develop and implement new, more effective strategies and tools for their prevention, diagnosis and treatment.

In recent decades, medical innovations have played a key role in improving prognoses and reducing the spread of infectious diseases. However, with the emergence of new pathogens, as well as the evolution of existing ones, the need for constant development of new approaches becomes extremely urgent. This is what ensures the constant desire of the medical and scientific communities to search for innovative solutions<sup>2</sup>.

The purpose of the work is to provide an overview of modern medical innovations that are aimed at effectively combating infectious diseases. The key strategies of prevention, diagnosis and treatment, as well as their role in modern medical practice, will be considered. The main attention is paid to new methods of vaccination, diagnosis and therapy, as well as to the analysis of their prospects in the context of modern challenges such as emergent infections and antibiotic resistance.

## Materials and methods

In the process of writing an extensive review of modern scientific articles, reviews, books and other publications related to medical innovations in the field of combating infectious diseases was carried out. The results of clinical studies on new methods of prevention, diagnosis and treatment of infectious diseases were also studied. This will allow us to evaluate the effectiveness and safety of various therapeutic approaches. The analysis of databases of medical research, such as PubMed, was carried out to find up-to-date information on the latest medical innovations in the fight against infectious diseases. Statistical data on the spread of infectious diseases, including data on morbidity, mortality, and the spread of drug resistance, are analyzed.

## Results

Modern strategies for combating infectious diseases are based on advanced scientific and technological achievements. They include several key areas. Vaccination plays an important role, and here the development of new types of vaccines, such as RNA vaccines and vector vaccines, provides a faster and more effective formation of the immune response<sup>3</sup>. Genetic engineering technologies are also being used to create safe and effective vaccines, as well as to enhance the immune response.

Molecular technologies, such as PCR and genome sequencing, play an essential role in diagnosis, which provide more accurate and rapid detection of pathogens of infectious diseases. Biosensors and microfluidic technologies also allow for accurate on-site diagnostics<sup>4</sup>.

Antimicrobials with new mechanisms of action are used in the treatment of infections to expand the spectrum of activity and reduce the likelihood of developing resistance. Monoclonal antibodies and immunomodulators are used to enhance the immune response and fight infection. Gene therapy and genome editing technologies provide a more accurate and personalized approach to treatment<sup>5</sup>.

Preventing the spread of infections also plays a key role. Innovative hygiene and disinfection methods, such as ultraviolet irradiation and nanotechnology, help prevent the spread. The development of integrated monitoring and control systems makes it possible to quickly identify and prevent epidemics.

These strategies represent an integrated approach to the fight against infectious diseases, which requires not only the development of new methods, but also their widespread introduction into healthcare practice, as well as constant monitoring and adaptation to the changing epidemiological situation<sup>6</sup>.

The latest diagnostic methods for infectious diseases include advanced technologies that significantly improve the accuracy and speed of pathogen detection. Molecular technologies such as PCR and IANK make it possible to quickly and accurately identify the genetic material of pathogens, which is especially important for viruses, bacteria and fungi.

Biosensors, including electrochemical and optical ones, provide sensitive pathogen detection methods that can be used to analyze clinical samples such as blood or urine.

The use of artificial intelligence, such as machine learning methods and deep learning algorithms, makes it possible to process large amounts of data and automatically

identify patterns associated with infections<sup>7</sup>. This significantly increases the speed and accuracy of diagnosis.

These advanced diagnostic methods not only provide more accurate and rapid detection of infections, but also help to start treatment earlier, which ultimately contributes to the control and prevention of the spread of diseases. The use of such advanced technologies in combination with artificial intelligence opens up new prospects in the diagnosis of infectious diseases and increases the effectiveness of their control<sup>8</sup>.

Advanced treatments for infectious diseases include a variety of approaches, including the use of antimicrobials. Antibiotics play a key role in the treatment of bacterial infections, but with the emergence of resistance to them, it becomes necessary to develop new drugs and strategies to manage resistance. Antiviral drugs are used to reduce the symptoms and duration of viral infections<sup>9</sup>. Antifungal drugs are used to treat fungal infections such as candidiasis and aspergillosis.

Monoclonal antibody therapy is the use of special antibodies directed against specific pathogens or their toxins<sup>10</sup>. This method may be effective for the treatment of some viral and bacterial infections. Immunomodulators, in turn, can enhance or suppress the body's immune response, which is used to fight infection or reduce inflammation and autoimmune reactions.

Gene therapy and genome editing technologies represent innovative approaches to treatment. Gene therapy involves the use of genetic methods to treat or prevent diseases, such as the introduction of new genes, correction of mutations, or suppression of the expression of certain genes<sup>11</sup>. Genome editing technologies such as CRISPR-Cas9 make it possible to precisely change the DNA sequence in the genome of an organism, which opens up new opportunities for the treatment of genetic and infectious diseases by correcting genetic defects or eliminating pathogens<sup>12</sup>.

These advanced treatments represent powerful tools in the fight against infectious diseases and have the potential to significantly improve treatment outcomes and prognoses for patients. However, their effectiveness requires further research and clinical trials.

## Discussion

**D**octors and researchers in various fields of medicine actively apply advanced methods of treating infectious diseases in practice.

1. The use of monoclonal antibodies for the treatment of COVID-19. During the COVID-19 pandemic, clinical trials of monoclonal antibodies against the SARS-CoV-2 virus were conducted. This method of therapy allows to reduce the severity of the disease and prevent its progression in seriously ill patients.
2. Gene therapy for the treatment of genetic forms of immunodeficiency. Gene therapy has been successfully used to treat rare genetic forms of immunodeficiency, which can make patients more susceptible to infections. This approach makes it possible to make adjustments to the genetic material, improving the function of the immune system<sup>13</sup>.
3. Antimicrobials with new mechanisms of action. The pharmaceutical industry is actively developing antibiotics and antiviral drugs with new mechanisms of action that can be effective in treating infections caused by resistant strains of microorganisms<sup>14</sup>.
4. Real-time molecular diagnostics technologies. Molecular diagnostic methods such as PCR and genome sequencing are actively used in clinical practice to quickly and accurately identify infectious agents, which allows targeted treatment to begin immediately.
5. Development of vaccines using new technologies. Recent advances in vaccine development, such as mRNA-based vaccines and vector vaccines, reflect cutting-edge scientific advances in immunology and genetic engineering. These vaccines ensure the rapid and effective formation of an immune response against infectious agents.
6. The use of biosensors for the diagnosis of infections. Biosensors are becoming an increasingly common tool for rapid diagnosis of infections. They allow for on-site analysis of the patient's biomaterial, which reduces the time to obtain results and allows treatment to begin immediately<sup>15</sup>.
7. The use of artificial intelligence technologies to predict the spread of infections. Artificial intelligence is used to analyze data on the spread of infections and predict their future spread. This helps healthcare organizations develop more effective strategies to prevent epidemics.
8. Innovative methods of treatment of viral hepatitis. New drugs and treatments for viral hepatitis, including hepatitis C and B viruses, are under development. These methods are aimed at eliminating the virus from the body and preventing the development of complications<sup>16</sup>.

9. The use of phage therapy. Bacteriophage therapy, or simply phage therapy, is attracting attention again. It is a treatment method based on the use of bacteriophages to kill bacterial infections, and it can be an alternative or supplement to antibiotics.

10. The development of personalized medicine in the treatment of infections. With the development of genetic research and genome sequencing technologies, it becomes possible to apply personalized approaches to the treatment of infections. This includes determining individual drug sensitivity and developing individual therapy regimens.

These examples demonstrate that advanced treatments for infectious diseases are constantly evolving and finding their application in clinical practice, increasing the effectiveness of treatment and improving patient outcomes.

Each of the strategies in the fight against infectious diseases has its own potential advantages and limitations, and their role in modern medical practice can be significant. Antimicrobials can quickly and effectively control infection, saving patients' lives<sup>17</sup>. They are widely available and available in various forms, which facilitates their use. However, the growing problem of antibiotic resistance may reduce the effectiveness of this strategy. In addition, the use of antimicrobials may be accompanied by side effects and the development of recurrent infections.

Monoclonal antibodies can be pathogen-specific and have fewer side effects than other treatments. They can also ensure the rapid and effective elimination of infection<sup>18</sup>.

At the same time, the stability and long duration of action of monoclonal antibodies may be limited. In addition, the development and production of monoclonal antibodies can be expensive and require specialized equipment.

Immunomodulators can improve the body's immune response to infection and reduce inflammation. They can be used to suppress or enhance an overactive immune response, depending on the nature of the infection. However, undesirable side effects and the possibility of developing autoimmune reactions are potential limitations of the use of immunomodulators<sup>19</sup>.

Gene therapy and genome editing have the potential to correct genetic defects associated with vulnerability to infections, as well as to eliminate pathogens by directly altering their genetic information. However, these technologies are still in development, and their safety and effectiveness must be thoroughly investigated. In addition, ethics and accessibility issues may limit their widespread use<sup>20</sup>.

The role of these strategies in modern medical practice is to provide doctors and patients with effective tools to combat infectious diseases, improve treatment outcomes and prevent the spread of diseases. The pros-

pects for future research and development include further improvement of existing methods, the development of new technologies and strategies, as well as their wider implementation in practice in order to improve healthcare.

A constant innovative approach plays a critical role in combating the growing challenges of infectious diseases on a global scale for several reasons. Infectious agents are constantly evolving, adapting to changing conditions and the response of the immune system. Innovative methods help to develop new strategies for the treatment and control of the spread of infections in response to these changes.

Increasing resistance to antibiotics and other antimicrobial drugs jeopardizes the effectiveness of infection treatment. Continuous development of new antimicrobial drugs and treatments is necessary to overcome this problem. Infectious diseases can spread rapidly across borders, posing a threat to public health worldwide. Innovative approaches help to develop more effective methods of diagnosis, vaccination and epidemic control<sup>21</sup>.

Innovations in the field of healthcare can contribute to the development of sustainable health systems that can effectively respond to sudden threats and quickly introduce new methods of diagnosis, prevention and treatment. Global cooperation is also necessary to effectively overcome the challenges of infectious diseases<sup>22</sup>.

Joint research and exchange of experience between scientific communities and medical organizations from different countries can help spread best practices and solutions. Cooperation allows for more efficient use of resources and infrastructure for the development and implementation of innovations, especially in countries with limited resources<sup>23</sup>.

Global cooperation allows for a rapid and coordinated response to epidemics and pandemics, preventing their spread and minimizing damage to health and the economy<sup>24</sup>.

In general, continuous innovative development combined with global cooperation play a key role in combating the challenges associated with infectious diseases and contribute to improving the health of people around the world.



Infectious diseases remain one of the main challenges for public health worldwide, requiring constant attention and innovative approaches to combat them.

Continuous innovative development in the field of medicine plays a key role in overcoming the challenges associated with infectious diseases. New methods of diagnosis, treatment and prevention, such as RNA vaccines, monoclonal antibody therapy, gene therapy and genome editing technologies, contribute to a more effective fight against infectious diseases.

Global cooperation is essential to effectively address the challenges of infectious diseases. The exchange of knowledge, resources and experience between countries, and the joint response to epidemics and pandemics contribute to the development and implementation of advanced methods to combat infections and minimize their impact on public health.

Despite the successes achieved, infectious diseases continue to pose a serious threat to public health. Therefore, it is necessary to continue investing in scientific research, the development of new methods and technologies, as well as strengthen global cooperation to ensure effective control of infectious diseases and create a safe and healthy world for all.

## References

1. Stearns SC. Evolutionary medicine: Its scope, interest and potential. *Proc R Soc B* (2012) 279:4305–21.
2. Grunspan DZ, Moeller KT, Nesse RM, Brownell SE. The state of evolutionary medicine in undergraduate education. *Evol Med Public Heal* (2019) 2019:82–92.
3. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, et al. Classifying the evolutionary and ecological features of neoplasms. *Nat Rev Cancer* (2017) 17:605–19.
4. Kennedy DA, Read AF. Monitor for COVID-19 vaccine resistance evolution during clinical trials. *PLoS Biol* (2020) 18:1–5.
5. Stenvinkel P, Painer J, Johnson RJ, Natterson-Horowitz B. Biomimetics – nature's roadmap to insights and solutions for burden of lifestyle diseases. *J Intern Med* (2020) 287:238–51. doi: 10.1111/joim.12982
6. Natterson-Horowitz B, Desmarchelier M, Winkler AS, Carabin H. Beyond zoonoses in one health: Non-communicable diseases across the animal kingdom. *Front Public Heal* (2022) 9:807186.
7. Pesavento PA, Agnew D, Keel MK, Woolard KD. Cancer in wildlife: Patterns of emergence. *Nat Rev Cancer* (2018) 18:646–61.
8. Gluckman PD, Low FM, Hanson MA. Anthropocene-related disease the inevitable outcome of progressive niche modification. *Evol Med Public Heal* (2020) 2020:304–10.
9. Vincze O, Colchero F, Lemaître JF, Conde DA, Pavard S, Bieuville M, et al. Cancer risk across mammals. *Nature* (2022) 601:263–7.
10. Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. *Nat Commun* (2020) 11:5799.
11. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Fink S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature* (2021) 591:639–44.
12. Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. *Nat Rev Clin Oncol* (2020) 17:675–86.
13. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. *Cancer Drug Resist* (2019) 2(2):141–60.
14. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *Lancet* (2022) 399:P629–665.
15. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respir Med* (2017) 5:291–360.
16. Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: A systematic review of randomized controlled trials. *Pharmacotherapy* (2018) 38:674–87.
17. Hansen E, Read AF. Cancer therapy: Attempt cure or manage drug resistance? *Evol Appl* (2020) 13:1660–72.
18. Graf FE, Palm M, Warringer J, Farewell A. Inhibiting conjugation as a tool in the fight against antibiotic resistance. *Drug Dev Res* (2019) 80:19–23.
19. Morley VJ, Kinnear CL, Sim DG, Olson SN, Jackson LM, Hansen E, et al. An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. *Elife* (2020) 9:1–17.
20. Hansen E, Karslake J, Woods RJ, Read AF, Wood KB. Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations. *PLoS Biol* (2020) 18:1–20.
21. Torres-Barceló C, Turner PE, Buckling A. Mitigation of evolved bacterial resistance to phage therapy. *Curr Opin Virol* (2022) 53:101201.
22. Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. *Cell Host Microbe* (2019) 25:219–32.
23. Kunttu HMT, Runtuvuori-Salmela A, Sundell K, Wiklund T, Middelboe M, Landor L, et al. Bacteriophage resistance affects *Flavobacterium columnare* virulence partly via mutations in genes related to gliding motility and the type IX secretion system. *Appl Environ Microbiol* (2021) 87:e00812–21.
24. Burmeister AR, Fortier A, Roush C, Lessing AJ, Bender RG, Barahman R, et al. Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. *Proc Natl Acad Sci USA* (2020) 117:11207–16.